Franklin Biotechnology Discovery Fund Class C (FBTDX)
| Fund Assets | 676.00M |
| Expense Ratio | 1.80% |
| Min. Investment | $1,000 |
| Turnover | 35.87% |
| Dividend (ttm) | 11.76 |
| Dividend Yield | 10.90% |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 20, 2024 |
| Previous Close | 106.95 |
| YTD Return | 0.01% |
| 1-Year Return | -6.23% |
| 5-Year Return | -10.27% |
| 52-Week Low | 89.43 |
| 52-Week High | 139.40 |
| Beta (5Y) | n/a |
| Holdings | 88 |
| Inception Date | Mar 4, 2014 |
About FBTDX
Franklin Biotechnology Discovery Fund Class C is an actively managed mutual fund specializing in the biotechnology sector. The fund's primary objective is capital appreciation, achieved by investing at least 80% of its net assets in equity securities of biotechnology companies and discovery research firms. It targets firms that derive at least half of their revenue from biotechnology-related activities, making it deeply focused within the life sciences industry. As a health-category fund, it offers exposure to both domestic and international companies engaged in drug development, therapeutic innovation, and related scientific advancements, with nearly half of its assets frequently concentrated in its top ten holdings across major biotech players. Since its inception in 2014, the fund has provided investors with access to a dynamic and rapidly evolving sector known for both its growth potential and volatility. Managed by Franklin Templeton Investments, the fund appeals to market participants seeking dedicated access to the biotechnology industry’s innovation cycle within the broader healthcare landscape.
Performance
FBTDX had a total return of -6.23% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.58%.
Top 10 Holdings
49.47% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 8.17% |
| Amgen Inc. | AMGN | 7.64% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.25% |
| Ascendis Pharma A/S | ASND | 4.89% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.34% |
| argenx SE | ARGX | 3.80% |
| Jazz Pharmaceuticals plc | JAZZ | 3.79% |
| Merus N.V. | MRUS | 3.52% |
| PTC Therapeutics, Inc. | PTCT | 3.16% |
| Neurocrine Biosciences, Inc. | NBIX | 2.91% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2024 | $11.7607 | Dec 20, 2024 |
| Dec 15, 2021 | $16.6721 | Dec 15, 2021 |
| Dec 15, 2020 | $10.3921 | Dec 15, 2020 |
| Dec 16, 2019 | $14.1643 | Dec 18, 2019 |
| Dec 17, 2018 | $4.5496 | Dec 19, 2018 |
| Dec 15, 2017 | $3.5969 | Dec 19, 2017 |